4-氯-2-二甲基氨基-1,3-噻唑-5-甲醛 | 129865-54-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 中文名称: 4-氯-2-二甲基氨基-1,3-噻唑-5-甲醛
• 中文别名: 4-氯-2-(二甲基氨基)-1,3-噻唑-5-甲醛
• 英文名称: 4-chloro-2-(dimethylamino)thiazole-5-carbaldehyde
• 英文别名: 4-Chloro-2-(dimethylamino)-1,3-thiazole-5-carbaldehyde
• CAS: 129865-54-9
• 化学式: C₆H₇ClN₂OS
• mdl: MFCD07852062
• 分子量: 190.653
• InChiKey: WQEAFACWNKVEMO-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.2
• 重原子数：
  11
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.333
• 拓扑面积：
  61.4
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  4-氯-2-二甲基氨基-1,3-噻唑-5-甲醛 在 potassium carbonate 作用下， 以 甲醇 、 水 为溶剂， 反应 18.5h， 生成 4‑[4‑methoxy‑2‑(dimethylamino)thiazol‑5‑yl]but‑3‑en‑2‑one
  参考文献：
  名称：

  2,4-二取代的4-（1,3-噻唑-5-基）丁-3-烯-2-酮：合成方法及其化学修饰

  摘要：

  摘要亚芳基酮通常被认为是用于获得具有潜在药用价值的化合物的方便的起始原料。该系列的杂环α，β-不饱和代表具有值得详细研究的化学和生物学特性。特别地，结合到这样的系统中的取代的噻唑循环允许获得适合于其随后的化学修饰的新的生物活性产物。在本交流中，我们将注意力集中在2,4-二卤素-5-甲酰基噻唑的背景上的2,4-二取代的4-（1,3-噻唑-5-基）but-3-en-2-ones上，其中一些相关合成方法以及进一步化学修饰的预期方向。 图形摘要

  DOI：

  10.1007/s00706-020-02612-7
• 作为产物：
  描述：

  2,4-二氯噻唑 、 N,N-二甲基甲酰胺 在 正丁基锂 作用下， 生成 4-氯-2-二甲基氨基-1,3-噻唑-5-甲醛
  参考文献：
  名称：

  Sawhney, Indu; Wilson, John R. H., Journal of the Chemical Society. Perkin transactions I, 1990, # 2, p. 329 - 331

  摘要：

  DOI：

文献信息

• [EN] IMIDAZO [4, 5 - B] PYRIDINE DERIVATIVES AS ALK AND JAK MODULATORS FOR THE TREATMENT OF PROLIFERATIVE DISORDERS<br/>[FR] DÉRIVÉS IMIDAZO [4,5-B] PYRIDINE COMME MODULATEURS D'ALK ET DE JAK POUR LE TRAITEMENT DE TROUBLES PROLIFÉRATIFS
  申请人：CEPHALON INC

  公开号：WO2013116291A1

  公开（公告）日：2013-08-08

  This application relates to compounds of the Formula I as defined herein, and/or salts thereof. This application further relates to compositions and methods of using these compounds and/or salts thereof. The compounds of Formula I are useful as ALK and JAK modulators for the treatment of proliferative disorders.

  这项申请涉及到本文所定义的Formula I化合物及/或其盐。此申请进一步涉及到使用这些化合物和/或其盐的组合物和方法。Formula I化合物可用作ALK和JAK调节剂，用于治疗增殖性疾病。
• Imidazo[4,5-b]pyridine Derivatives as ALK and JAK Modulators for the Treatment of Proliferative Disorders
  申请人：Cephalon, Inc.

  公开号：US20140350011A1

  公开（公告）日：2014-11-27

  This application relates to compounds of the Formula I as defined herein, and/or salts thereof. This application further relates to compositions and methods of using these compounds and/or salts thereof. The compounds of Formula I are useful as ALK and JAK modulators for the treatment of proliferative disorders.

  本申请涉及公式I所定义的化合物和/或其盐。本申请还涉及使用这些化合物和/或其盐的组合物和方法。公式I的化合物可用作ALK和JAK调节剂，用于治疗增生性疾病。
• Imidazo[4,5-b]pyridine derivatives as ALK and JAK modulators for the treatment of proliferative disorders
  申请人：Cephalon, Inc.

  公开号：US09238656B2

  公开（公告）日：2016-01-19

  This application relates to compounds of the Formula I as defined herein, and/or salts thereof. This application further relates to compositions and methods of using these compounds and/or salts thereof. The compounds of Formula I are useful as ALK and JAK modulators for the treatment of proliferative disorders.

  本申请涉及公式I所定义的化合物及/或其盐。本申请还涉及使用这些化合物和/或其盐的组合物和方法。公式I的化合物可用作ALK和JAK调节剂，用于治疗增殖性疾病。
• Bi-functional complexes and methods for making and using such complexes
  申请人：Gouliaev Alex Haahr

  公开号：US11225655B2

  公开（公告）日：2022-01-18

  The present invention is directed to a method for the synthesis of a bi-functional complex comprising a molecule part and an identifier oligonucleotide part identifying the molecule part. A part of the synthesis method according to the present invention is preferably conducted in one or more organic solvents when a nascent bi-functional complex comprising an optionally protected tag or oligonucleotide identifier is linked to a solid support, and another part of the synthesis method is preferably conducted under conditions suitable for enzymatic addition of an oligonucleotide tag to a nascent bi-functional complex in solution.

  本发明涉及一种合成双功能复合物的方法，该复合物包括分子部分和识别分子部分的识别寡核苷酸部分。根据本发明的合成方法的一部分优选在一种或多种有机溶剂中进行，此时包含可选保护标签或寡核苷酸标识符的新生双功能复合物与固体支持物相连接，合成方法的另一部分优选在适合于将寡核苷酸标签酶加到溶液中的新生双功能复合物的条件下进行。
• Discovery of thienothiazolocarboxamide analogues as novel anti-tubercular agent
  作者：Guanghai Jin、Young Mi Kim、Aram Lee、Junghwan Choi、Sunhee Kang、Mooyoung Seo、Jeong Jea Seo、Sumi Lee、Juhee Kang、Jaeseung Kim、Sinyoung Park、Minjeong Woo、Virgínia Carla de Almeida Falcão、Honggun Lee、Jinyeong Heo、David Shum、Kaapjoo Park、Vincent Delorme、Inhee Choi

  DOI：10.1016/j.bmc.2020.115797

  日期：2020.12

  In order to identify anti-tubercular agents with a novel scaffold, commercial libraries of small organic compounds were screened against a fluorescent strain of Mycobacterium tuberculosis H37Rv, using a dual phenotypic assay. Compounds were assessed against bacteria replicating in broth medium, as well as inside macrophages, and thienothiazolocarboxamide (TTCA) scaffold was identified as hit in both assays, with submicromolar inhibitory concentrations. Derivatives of TTCA were further synthesized and evaluated for their inhibitory effects on M.tuberculosis H37Rv. In the present study we report the structure-activity relationship of these TTCA derivatives. Compounds 28, 32 and 42 displayed good anti-tubercular activities, as well as favorable ADME and PK properties. Compound 42 exhibited excellent oral bioavailability in mice with high distribution to lungs, within 1 h. It was found to be efficacious in a dose dependent manner in a murine model of M. tuberculosis infection. Hence, compound 42 is now under evaluation as a potential lead candidate for treatment of tuberculosis.